Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.76 USD | -5.15% | -5.48% | -14.02% |
Financials (USD)
Sales 2024 * | 42.75K | Sales 2025 * | 4.41M | Capitalization | 471M |
---|---|---|---|---|---|
Net income 2024 * | -283M | Net income 2025 * | -305M | EV / Sales 2024 * | 5,174 x |
Net cash position 2024 * | 250M | Net cash position 2025 * | 284M | EV / Sales 2025 * | 42.4 x |
P/E ratio 2024 * |
-1.65
x | P/E ratio 2025 * |
-1.66
x | Employees | 233 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.22% |
Latest transcript on Allogene Therapeutics, Inc.
1 day | -5.15% | ||
1 week | -5.48% | ||
1 month | -30.65% | ||
3 months | -36.84% | ||
6 months | -3.50% | ||
Current year | -14.02% |
Managers | Title | Age | Since |
---|---|---|---|
Joshua Kazam
FOU | Founder | 47 | 17-10-31 |
David Chang
FOU | Founder | 64 | 18-03-31 |
Geoffrey Parker
DFI | Director of Finance/CFO | 59 | 23-10-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Bonderman
BRD | Director/Board Member | 81 | 18-04-30 |
Joshua Kazam
FOU | Founder | 47 | 17-10-31 |
Arie Belldegrun
FOU | Founder | 74 | 17-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.54% | 2 M€ | -25.75% | ||
0.08% | 0 M€ | 0.00% | - | |
0.06% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 2.76 | -5.15% | 1,141,019 |
24-05-07 | 2.91 | -3.32% | 866,952 |
24-05-06 | 3.01 | -1.95% | 1,566,317 |
24-05-03 | 3.07 | +3.37% | 1,336,548 |
24-05-02 | 2.97 | +1.71% | 1,400,492 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.02% | 471M | |
+2.93% | 108B | |
-3.52% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |
- Stock Market
- Equities
- ALLO Stock